Introduction
Angiogenesis plays a fundamental role in many physiological processes, including ischemia, wound healing, regeneration of injured tissues, and embryonic development. The complex cascade of events involved implicates the disruption of vascular basement membranes, migration and proliferation of endothelial cells, and finally the formation and maturation of new blood vessels. 1 FGF2 or bFGF is a member of the fibroblast growth factor family which promotes angiogenesis in vitro and in vivo. 2 The human bFGF gene is expressed at minimum as four forms ranging from 155 to 210 amino acids long, produced by alternative initiations of translation. 3 Each isoform seems to have an important role in the different bFGF localizations and functions. The shortest protein (18 kDa), mostly cytosolic, can be secreted despite the absence of a signal sequence. It mediates an autocrine or a paracrine effect after interaction with the bFGF membrane receptors. Higher molecular weight forms of bFGF, containing a nuclear localization sequence in the additional region, are not released from the cells and have an intracrine effect independent of the cell surface receptors. 4, 5 The 18 kDa form may be the primary mediator of changes in endothelial cell behavior since it enhances both cell proliferation and migration and protease production, and also modulates integrin expression. However, the larger nuclear forms may act as further mediators of endothelial cell proliferation during angiogenesis. 6 Revascularization of small or widely diffuse diseased vessels is generally unsuccessful, and current medical treatments have proved largely ineffective. Recently, different reports have demonstrated the interest of using angiogenic growth factors to increase collateral artery development. This strategy has been used both in animal models of hindlimb and myocardial ischemia and more recently in clinical trials to induce therapeutic angiogenesis. [7] [8] [9] However, the wide cellular spectrum and the pleiotropic function of bFGF make its continuous and local production following gene transfer preferable, over administration of repetitive and large doses of the recombinant protein. Different strategies have been suggested to date to express therapeutic transgenes in fully differentiated tissues. Replication-deficient adenoviruses have been recently used to transfer various genes coding other potent angiogenic factors. [10] [11] [12] [13] [14] [15] Ad vectors present several advantages including: (1) a low pathogenicity in nonimmunosuppressed individuals; (2) a high capacity to accept foreign DNA; (3) high viral titers; (4) an efficient gene expression in quiescent cells such as skeletal muscle fibers or cardiomyocytes and (5) a transient expression in dividing cells, which is particularly adapted to the time course of vessel neoformation. 16 In counterpart, adenovirus vectors induce inflammatory and immune responses and the current vectors employed are not tissue specific. 17 In the present study we have demonstrated that the bFGF isoforms can be expressed in a fully functional manner in cultured myoblasts or muscle fibres infected with a replication-deficient adenovirus bearing the human bFGF (Ad-RSVbFGF). Furthermore, this recombinant bFGF was shown to stimulate directly endothelial cells in an in vitro model of angiogenesis, and to induce neoangiogenesis locally after either subcutaneous administration of Matrigel or intramuscular injection of mice.
Results
Construction of the recombinant adenoviral vector Ad-RSVbFGF A 1.62 kb long region of the bFGF cDNA (6.3 kb) obtained from the human hepatoma cell line SK-HEP-1 was used for the construction of the recombinant virus Ad-RSVbFGF. 18 In addition to the ATG-initiated coding region of the gene, this sequence includes in its 5Ј end a 71 nucleotide long region containing several CTGs normally used as alternative initiation codons, resulting in the production of larger isoforms containing nuclear localization sequences. The 3Ј untranslated region contains only the first polyadenylation signal of the bFGF gene with a relatively small portion (984 nucleotides) of the very long 3Ј sequence (4.8 kb) existing in the cDNA and which is probably involved in regulation of mRNA stability. 18 The human bFGF cDNA sequence was positioned under the control of the RSV promoter. The replication-deficient recombinant Ad-RSVbFGF was obtained by in vivo homologous recombination in 293 cells between the recombinant plasmid and viral DNA.
Expression of bFGF in cell culture
Western blotting analyses were conducted to measure expression of the bFGF gene in different infected cell types: 293, a human cell line allowing replication of the E1-defective recombinant Ad (Figures 1a and b, lanes 1-4) , HeLa, a non-complementing human cell line ( Figure  1a, lanes 7, 8) and C2, a mouse myoblast cell line ( Figure  1a and b, lanes 5 and 6). Three specific bands corresponding to the relative molecular masses 18K, 22.5K and 24-25K indicative of the bFGF isoforms were detected by immunotransfer of extracts from Ad-RSVbFGF-infected cells (Figure 1a, lanes 3, 6, 8 ). In contrast, no detectable signal was observed in other lanes corresponding either to uninfected cells (lane 1) or to Ad-RSV␤gal-infected cells (lanes 2, 5, 7). The position of each band is in agreement with the molecular weights described by others. 18, 19 Similar quantities of protein were found in the bands corresponding to the 18 kDa isoform in lane 6 and to the 16 kDa bFGF standard protein (20 ng) . ELISA quantification of bFGF found in extracts from Ad-RSVbFGF-infected 293 or C2 cells (15 and 7 ng/10 6 cells/24 h, respectively) confirmed the results obtained in Western blots.
We also immunotransferred proteins present in the conditioned medium of 293 (Figure 1b, lanes 3 and 4) and C2 (lanes 5 and 6) either concentrated (lanes 3 and 5) or not (lanes 4 and 6). Clearly, a specific band corresponding to the predicted size could be detected in the concentrated medium of C2 cells (lane 5). The very low levels of the larger isoforms indicated that the 18 kDa protein was truly secreted and was not the result of a large cellular destruction. In 293 cell-conditioned medium, the 18 kDa protein is difficult to detect in Western blots although it is observed in the corresponding cell extract (lane 1). The level of released bFGF ELISA in infected 293 and C2 cells was found with ELISA to be, respectively, 4 and 10 ng/10 6 cells/24 h, confirming these results. Comparing these values with those obtained for cell extracts, bFGF is more efficiently released from C2 (more than 50% of bFGF) compared with 293 cells. Moreover, it should be noted that bFGF is expressed in C2 nearly as efficiently as in 293 cells which allow replication of the recombinant virus.
Bioactivity of the recombinant bFGF protein
The functionality of the recombinant protein obtained from Ad-RSVbFGF-infected 293 or C2 cell extracts was tested in a long-term survival assay of density-arrested quiescent BALB/c-3T3 fibroblasts. When BALB/c-3T3 cells are incubated for 20 h with serum-free medium, there is a 97% decrease in viability compared with cells cultured in medium containing 10% serum (Figure 2a , controls). When three-fold dilutions of crude cell extracts from Ad-RSVbFGF-infected, Ad-RSV␤gal-infected or uninfected 293 cells were supplemented with serum-free medium, only the first were able to maintain survival of around 75% of BALB/c-3T3 cells at dilution 1/108, and 51% at the subsequent dilution (Figure 2a) . A non-specific enhancement of BALB/c-3T3 cell survival was observed at the lowest dilutions (1/4 and 1/12), probably because cell extracts contained levels of endogenous growth factors to maintain fibroblast survival (Figure 2a ). But at higher dilutions, cell survival of the control extracts was close to that of the serum-free control (6%). To determine whether bFGF is directly implicated in this effect, we performed an inhibition test using an anti-bFGF polyclonal antibody (Figure 2b ). We used Ad-RSVbFGF-infected C2 cell extracts diluted 1/200, because this is the lowest dilution able to maintain a 100% enhancement of fibroblast survival. The preincubation of extracts with a specific anti-bFGF antibody (at least at 10 g/ml) could completely neutralize their activity (Figure 2b ). Therefore, these results confirmed that Ad-RSVbFGF-infected 293 and C2 cell extracts possessed a marked cell survival enhancing activity, proportional to their levels of recombinant bFGF.
The concentration of active bFGF present in AdRSVbFGF-infected cell extracts can be calculated from the standard curve (not shown) by multiplying the concentration of the standard protein at the ED 50 by the dilution of extracts at the ED 50 . Values similar to those measured with ELISA were found for Ad-RSVbFGF-infected 293 and C2 cell extracts.
Capillary formation model
The model used in this study was established as described by Pepper et al 20 Table 1 a significant (P = 0.0003) 80% increase in the mean tube length (unpaired Student's t test with n = 7) is shown.
Induction of angiogenesis after subcutaneous injection of Matrigel plugs containing Ad-RSVbFGF
The recombinant virus activity in vivo was first tested after subcutaneous injection with Matrigel in mice. Fourteen days after injection, the Matrigel plugs and the surrounding tissues were histologically examined. Along the interface between the hypodermis and Ad-RSV␤gal-injected Matrigel plugs, a thin layer of connective tissue without vessel formation was observed ( Figure 4a ). Next to the abdominal muscle a similar pattern was observed ( Figure 4b ). Similar results were observed in tissues surrounding Matrigel plugs injected with vehicle alone (data not shown). In contrast, animals bearing Ad-RSVbFGFinjected Matrigel plug exhibited an abundant granulomatous tissue next to the skin. A major thickening of this layer was observed, including neoformed capillaries, fibroblast proliferation and increased production of stromal matrix (Figure 4c ). The fibres of the skin muscle, normally visible in the control animals sections ( Figure 4b ) were completely surrounded by the connective tissue containing abundant capillaries and venules with a visible endothelial lining ( Figure 4e ). Next to the abdominal wall, along the Matrigel, the connective tissue layer showed a less significant thickening but, nevertheless, an increased cellularity, and hyperplastic venules with protruding endothelial cells were observed ( Figure 4d ). Numerous fibroblasts and several foci of hyperplastic arterioles and venules were found exclusively within the Ad-RSVbFGF-injected Matrigel plugs (Figure 4f ). An average of 23.0 ± 3.6 capillaries/mm 2 (mean ± s.e.m. with n = 5) was detected in the Ad-RSVbFGF-injected Matrigel plugs as compared with none detected in the AdRSV␤gal-injected group.
Expression of bFGF after intramuscular injection of AdRSVbFGF
Immunohistochemistry was performed in order to assess bFGF expression in the muscle and its cellular localization. Extracellular and nuclear staining were both The lengths of five to 10 capillary tube-like structures of several aggregates were measured on slide projections. The figure for each independent aggregate was the mean of these lengths. Mean values of the data (± s.e.m.) were indicated at the bottom of each column. ***A significant difference (P = 0.0003) in the mean tube length was observed between Ad-RSVbFGF-infected CPAE aggregates and Ad-RSV␤gal-infected CPAE aggregates (unpaired Student's t test with n = 7).
present in Ad-RSVbFGF-injected muscles (Figure 5a and b). A specific nuclear staining was observed with two different antibodies. Moreover, the antibody directed against bovine bFGF detected several regions of the muscle presenting extracellular bFGF (Figure 5a ). The antibody directed against human bFGF was much more efficient in detecting its nuclear localization (Figure 5b ). In contrast, contralateral muscles injected with AdRSV␤gal showed no nuclear staining and only a weak staining in the extracellular matrix (Figure 5c ). In the serial section of the muscle, the same zones negative for anti-bFGF antibodies were, nevertheless, found positive for anti-␤-galactosidase (Figure 5d ), indicating that injec- 
Figure 4 Histologic sections of the Matrigel plugs and surrounding tissues. Plugs containing either Ad-RSV␤gal (a and b) or Ad-RSVbFGF (c-f) were sectioned and slides were stained with hematoxylin-eosin-saffron. Views are shown of the control Matrigel plugs towards the skin (a) or in the vicinity of the abdominal muscle (b) and Ad-RSVbFGF-containing plugs towards the skin (c, e), next to the abdominal muscle (d), or inside the Matrigel plug itself (f). Thickness of the stromal matrix layer is indicated by a bracket in (a). Neoformed, red blood cell-containing vessels are indicated by arrows in (c). The stars show the location of Matrigel. Original magnification ×200 (a-c) and ×400 (d-f).
tion of the adenovirus vector itself is not responsible for the bFGF expresssion observed. We confirmed with ELISA that injection of the gastrocnemius muscle with Ad-RSV␤gal did not significantly increase the mean level of bFGF in muscle protein extracts (m = 266 pg/mg of protein) as compared with sham-treated muscle injected with PBS (m = 250 pg/mg of protein). However, administration of Ad-RSVbFGF in the muscle produced a significant (P = 0.05) 2.5-fold increase in the mean bFGF concentration (paired Student's t test with n = 4). Nevertheless, no substantial increase was observed in the mean bFGF levels detected in the serum of treated animals compared with control animals (75 and 70 pg/ml of serum, respectively).
Ad-RSVbFGF-induced angiogenesis in the muscle
In Ad-RSV␤gal-injected muscle, vascularization consisted of scarce capillaries and single endothelial cells ( Figure  6a and b) . In contrast, Ad-RSVbFGF-injected muscle exhibited large and numerous vessels, including arterioles, venules and capillaries (Figure 6c-e) . Moreover, in treated animals, numerous neoformed, small-caliber ves-b a c d
Figure 5 ␤-Galactosidase and bFGF immunostaining on muscle sections. Muscles injected with Ad-RSVbFGF (a, b) or the contralateral muscle injected with Ad-RSV␤gal (c, d) were immunostained with different antibodies recognizing bFGF (a-c) or E. coli ␤-galactosidase (d). Anti-bFGF antibody AB-33-NA (R&D Systems) was used in (a) and (c). It showed both an intracellular and an extracellular matrix staining (a). Anti-bFGF antibody AB-233-NA (R&D Systems) detected mostly nuclear-located bFGF isoforms (b). No bFGF staining was observed in (c), but a nuclear ␤-galactosidase staining was detected in the adjacent section (d). The stars point out the same location in (c) and (d).
sels were specifically observed in the vicinity of regenerative fiber foci, characteristic of the mdx mouse myopathy. Enhancement of the vasculature was also achieved within the perimysium and adipose or connective tissues surrounding the muscular fascicles ( Figure 6f ). Finally, enumeration indicated a significant (P = 0.0012) 146% increase in the vasculature within muscle sections of the treated animals (paired Student's t test with n = 6). An average of 17 vessels/mm 2 was detected in Ad-RSVbFGF as compared with an average of seven vessels/mm 2 in the Ad-RSV␤gal-injected group (see Table 2 ).
Discussion
Angiogenesis, the process by which new capillary beds are formed from existing vessels, occurs in a wide range of important physiological and pathological situations. 1 Several growth factors and cytokines are implicated in the regulation of angiogenesis. Basic fibroblast growth factor is a potent mitogen for vascular endothelial and smooth muscle cells, and has been shown to promote angiogenesis in vitro and in vivo. Recent reports have demonstrated that this factor may also play an important role in accelerated vascularization after ischemia. Different studies have shown that higher levels of bFGF are present in cardiac and skeletal muscle tissues after ischemia.
21-23
Recombinant bFGF was reported to enhance angiogenesis and collateral vessel formation following acute arterial occlusion and to result in the salvage of infarcted myocardium in canine models. 24, 25 Basic FGF treatment of acute ischemic hindlimbs in rabbit or rat models using arterial ligation enhances angiogenesis, collateral vessel development, and muscle function. 26 The first clinical treatment with the bFGF protein resulted in myocardial revascularization in ischemic myocardium of patients with coronary disease. 9 In this report, we demonstrated by Western blot analysis and ELISA that at least three of the different isoforms of human bFGF (18K, 22.5K and 24-25K) are correctly expressed in different cell lines of various tissue origins after adenovirus-mediated gene transfer. The sizes of the specific bands are in general agreement with the molecular weights described by others. 18, 19 In our experiments, we were unable to detect the 23K species. Either the CTG initiating codon is rarely chosen by the translation machinery, or the gel does not allow a thorough resolution, making the 22.5K and 23K appear as a doublet. The variations in isoform levels observed between cell lines can reflect slight differences in the use of alternative initiation sites. Thus, the 18 kDa isoform, mainly cytosolic, appeared to be the most abundant form in the myoblast cell line. Nevertheless, it should be remembered that the affinity of the polyclonal antibody for different isoforms may vary, as was clearly observed on immunostaining of muscle sections with various polyclonal antibFGF antibodies. These results confirmed both the integrity of the construct and the conservation of its natural translation in cultured cells. We confirmed that although bFGF does not possess a signal peptide, the cytoplasmic 18 kDa form of the bFGF protein could be secreted into the medium of some cell lines. The underlying export mechanism of aFGF, bFGF and FGF-9 is not well known. Florkiewicz et al 27 have
shown that the biologically active 18 kDa bFGF isoform is selectively and quantitatively exported from intact cells via a unique cellular pathway, through an alternative energy-dependent non-ER/Golgi pathway. Jackson et al 28 have demonstrated that heat shock releases aFGF from cells. Sublethal membrane wounding and release of cytosolic bFGF without cell necrosis have also been documented in vivo after strenuous or eccentric contraction of normal and dystrophic muscle or in contraction-induced cell wounding in the heart. 29, 30 It is possible, although to date not formally proven, that the release of bFGF is particularly important in skeletal muscle and heart and is under the control of a physiological process. We have observed that levels of released bFGF are proportionally elevated in the conditioned medium of a myoblast cell ). For each muscle four to five fields were selected in three independent sections. The figures for both muscles from each animal were the means of these counts. Mean values of the data (± s.e.m.) are indicated at the bottom of each column. **A significant difference (P = 0.0012) was observed between right muscles injected with Ad-RSVbFGF and left muscles injected with Ad-RSV␤gal (paired Student's t test with n = 6).
line. Moreover, regions presenting an extracellular matrix localization of the bFGF were observed around non-necrotic myofibers in Ad-RSVbFGF-injected muscle. This suggests that the recombinant human bFGF was also secreted in vivo and can be stored in the extracellular matrix compartment. This result is interesting in view of an efficient paracrine effect of this factor in muscle.
As could be expected on account of the high degree of homology between bFGF from various species, recombinant human bFGF has been shown to be active in mouse cells. 31, 32 Ad-RSVbFGF-infected cell extracts were able to prolong the survival of density-arrested quiescent BALB/c 3T3 fibroblasts in a long-term survival assay. This effect was not induced by viral factors since AdRSV␤gal-infected cell extracts failed to maintain survival. Moreover, antibodies directed against human bFGF completely interfered with this activity. The data obtained here are similar to those described by Tamm et al 33 who used purified bFGF protein in an assay where the cell survival was 9.6% 24 h after addition of serum-free medium compared with 3% in our assay. The bFGF concentrations estimated in our functional assay were similar to those measured by ELISA, demonstrating that the recombinant proteins produced in vitro were mainly in a functional form.
We also demonstrated that Ad-RSVbFGF can induce a response in secondary cultures of normal endothelial cells. Different authors have shown that bFGF stimulates endothelial cell migration into a three-dimensional fibrin gel. 34, 35 This matrix has been used as an in vitro model to mimic closely the angiogenesis phenomenon since endothelial cells invade blood clots in the process of wound repair. 20, 36 In this gel aggregates of endothelial cells organize themselves to form characteristic tubes that resemble blood capillaries. Pepper et al 20 have shown that bFGF induces capillary lumen formation in this model, demonstrating the direct effect of this factor in angiogenesis. Using this model, we demonstrated that infection of CPAE cells with Ad-RSVbFGF increased the number and the mean length of capillary-like tubes around aggregates up to 80% compared with the controls. This result was not necessarily expected since (1) during the 6-day experiment, there is a dilution of the Ad-genome copy number with cell division, resulting in a lower bFGF expression and (2) we have observed that, in contrast to muscle cells, bFGF was not efficiently released from CPAE cells (data not shown). Moreover, an autocrine effect alone cannot account for migration and the capillary-like tube formation. Nevertheless, autocrine and paracrine effects seemed sufficient to increase the mean tube length.
Passaniti et al 37 showed that Matrigel alone persists for at least 10 days after a subcutaneous injection in mice, and produces neither an inflammatory nor an angiogenic response. In this study, the addition of angiogenic growth factors to Matrigel induced neovascularization within the Matrigel. In contrast, growth factors expressed from recombinant adenoviruses induced angiogenesis in the tissue surrounding the Matrigel. 10, 11 In the present study, Ad-RSVbFGF also induced vessel formation within the gel itself. This effect was associated with increased cellularity of the Matrigel, invaded mainly by fibroblasts that could be induced to proliferate. The formation of blood vessels was much more important in the granulomatous tissue next to the skin than in the tissue next to the abdominal muscle. This can be explained in part by the normal dermal vascularization but also by the accessibility of the skin muscle to the virus (absence of large connective wall between the Matrigel and skin). Neighboring skin myofibers can be infected by viral particles diffusing from the Matrigel and then locally release the angiogenic growth factor.
From a clinical standpoint, localized intramuscular transfer of the bFGF gene represents an interesting alternative to arterial or systemic injection of the recombinant protein. A phase I clinical trial in patients with critical limb ischemia indicated that intramuscular gene transfer of naked plasmid DNA encoding VEGF 165 is sufficient to induce therapeutic angiogenesis. 7, 38 Recombinant adenoviruses have been recently used to transfer different genes coding potent angiogenic factors. Angiogenesis was evaluated with a recombinant Ad expressing aFGF or VEGF either mixed with Matrigel and injected in subcutaneous position or after injection in rat adipose tissue. 10, 11, 13 An improvement in myocardial blood flow was reported after intracoronary injection of a recombinant adenovirus expressing FGF5 in the pig ischemic heart. 16 Recently, the recombinant Ad expressing VEGF 121 was shown to protect against ischemic vascular occlusion in a rat limb and to improve myocardial perfusion in the porcine ischemic heart. 14, 15 In the study at hand, the human bFGF gene was expressed under the control of the RSV promoter. We have shown that expression of RSV promoter-driven genes can last several weeks in immunocompetent hosts and several months in nude mice after intramuscular injections. 39 These results are compatible with the time-course of vessel neoformation. We injected the recombinant Ad into skeletal muscle of mdx mice. This route of injection was chosen since previous experiments failed to show any diffusion of the vector after intramuscular injections. 17, 39 In addition, adenovirus can mediate efficient gene transfer into muscle of adult mdx mice, as compared with normal adult mice. The myofiber necrosis-regeneration process in this model of Duchenne's myopathy results in the presence of numerous foci of immature fibers that are more efficiently infected by Ad vectors than are mature fibers. Moreover, this process mimics the situation observed in an ischemic muscle where necrosis is followed by active muscle regeneration. Another interesting potential of skeletal muscle is the progressive storage of released bFGF protein into the extracellular matrix.
An important goal of this work was to demonstrate that the intramuscular delivery of additional amounts of bFGF in a localized manner could result in detectable neoangiogenesis over a short time period (6 days). To document clearly expression of the human bFGF proteins in localized areas of the injected mouse muscle we used an immunohistochemical detection method. There is currently no antibody that can distinguish between human and mouse bFGF. Furthermore, it has been observed that bFGF expression is up-regulated in mdx mouse skeletal muscle and that increased levels of endogenous bFGF are present in the extracellular matrix, particularly in regenerating areas. 29, 40, 41 In our experiments, non-regenerating regions were also positively stained with different antibFGF antibodies in Ad-RSVbFGF-injected muscles. In addition, Ad-RSVbFGF-injected muscles showed both extracellular and specific nuclear staining whereas the contralateral muscle exhibited only scarce regions of extracellular staining. Quantitative determination of bFGF expression with ELISA in mdx mouse muscle confirmed the immunohistologic results. There was a significant increase (250% on average) in the levels of bFGF in Ad-RSVbFGF-treated muscle compared with contralateral or sham-injected muscles. In contrast, a specific increase in the level of bFGF was not detected in the serum of the treated animals. This observation was in agreement with the fact that intramuscular injection of adenovirus vectors provides a relatively localized gene transfer and that released bFGF can be trapped in the extracellular matrix of muscle. Immunohistologic quantification of vessel number showed a mean increase of 146% in the vessel number within the gastrocnemius injected with Ad-RSVbFGF compared with the contralateral hindlimb. Furthermore, arterioles and venules of the perimysium showed some degree of dilation of their lumens. These results confirmed the suggestion that bFGF possesses coronary and systemic vasodilator properties, raising the possibility that blood flow may also be increased by opening or increasing conductance of pre-existing collateral channels. 25 In our experiments, vessel formation occurred within 1 week after treatment.
This rapid process of vessel formation is in accordance with previous results indicating that coronary development can occur in dogs within 3 to 11 days after coronary occlusion. 24 Moreover, the short duration of treatment and the limitation of the systemic release of bFGF when adenovirus vector is injected locally in the muscle may have helped to minimize possible side-effects of bFGF expression in other tissues. Direct injection in the muscle could also be interesting in regard to the acute endothelial injury observed when high doses of recombinant adenovirus were used for gene transfer in the vasculature. 42, 43 Taken together, the data presented here demonstrate that a recombinant adenovirus harboring bFGF gene is capable of expressing the growth factor in a localized manner and during a short period of time in the muscle. This resulted in an increase in both vessel numbers and the proportion of large vessels in the injected muscle. The way is now open for the testing of similar routes of injection in large animal models of cardiac or hindlimb ischemia.
Materials and methods
Construction and purification of recombinant adenoviruses Construction of the recombinant adenovirus (Ad) AdRSV␤gal has been previously described. 16 The E1-defective virus Ad-RSVbFGF, expressing the bFGF cDNA under the control of the promoter of the Rous sarcoma virus (RSV) was constructed as follows. The plasmid pAd-RSVbFGF was obtained after subcloning of a XhoI/EcoRV fragment (1.62 kb) from the pSCT40 expression vector containing the sequence from nucleotide 295 to 1919 of the human bFGF cDNA isolated by Prats et al, 18 into the plasmid pAd-LTRIX cleaved by SalI and EcoRV. 39 The recombinant virus Ad-RSVbFGF was obtained by homologous recombination, plaque-purified twice and amplified about four to six times to prepare larger stocks as described. 17 Titers of the viral stocks were determined by plaque assay on 293 cells.
Cell line maintenance and infection 293 Cells were cultured in minimal essential medium (MEM) supplemented with 10% fetal calf serum (FCS) and non-essential amino acids. C2, HeLa and Balb/c-3T3 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS and 2 mm l-glutamine. Calf pulmonary artery endothelial cells (CPAE) were cultured in the same medium but supplemented with 20% FCS (complete medium) and used at passages 12 to 20. The cell lines were infected when 80% confluent in 75 cm 2 dishes. The recombinant viruses were added to cells for 1 h at the following multiplicities of infection (MOI): 25, 70, 400 and 600 MOI for 293, HeLa, C2 and CPAE cells, respectively. These MOI were chosen to infect nearly 100% of the cells. After additional incubations in fresh medium, cells or cell culture media were used for the detection of bFGF or for functional tests.
bFGF detection and quantification in infected cell cultures The cell culture media were concentrated five-fold with centrex UF filtres (Schleicher and Schuell, Dassel, Germany) and aliquots were stored at −80°C. The cells were washed in PBS and lysed in 0.4 ml of lysis buffer (1% Triton X100, 100 mm PMSF, 100 mm NH 4 OH in PBS pH 7.4). Cell debris were removed by centrifugation (15 000 g, 4°C, 20 min). The supernatants were diluted with 2% (w/v) SDS, 5 mm N-ethylmaleimide (NEM), 8 mm Tris-HCl pH 6.8, 125 mm NaCl, 2.5 mm EDTA, boiled for 5 min, divided into aliquots and stored at −80°C. The protein concentration was measured using the Bradford assay. 44 Protein samples (100 g) were mixed with 50 mm Tris-HCl pH 6.8, 2% (w/v) SDS, 20% glycerol, 1% ␤-mercaptoethanol, 0.05% (w/v) bromophenol blue and separated on a 12% SDS-polyacrylamide electrophoresis gel. The proteins were transferred to nitrocellulose membranes which were blocked for 2 h at room temperature (RT) in blocking buffer (5% (w/v) low fat milk, 0.05% Tween 20 in TBS), incubated at RT with an antihuman bFGF goat polyclonal antibody (R&D Systems, UK) diluted 1/2000 in the blocking buffer, and incubated for 1 h at RT with a peroxidase-conjugated rabbit antigoat IgG antibody diluted 1/600. Detection of antigenantibody complexes was carried out using the ECL bioluminescence kit (Amersham, UK). Quantification of the different bands from Western blots was obtained using a CCD camera acquisition and processing with the Gel Analyst software (Inconix/ Greystone).
An ELISA kit (sensitivity less than 1 pg/ml) was used for the quantification of bFGF (R&D Systems). No crossreactivity with other known cytokines was detected. The bFGF concentrations (expressed in ng of protein per 10 6 cells per 24 h) in the different cell extracts and conditioned media were measured as described in the protocol provided by the supplier.
Recombinant bFGF functional tests
Cell extracts were prepared from 8 × 10 6 293 or 3 × 10 6 C2 uninfected cells and from the same number of cells infected with either Ad-RSVbFGF or Ad-RSV␤gal as previously described. The cells were washed in PBS to remove any remaining FCS. Finally, the cells were resuspended in DMEM with 2 mm dithiotreitol and lysed by five cycles of freezing and thawing. The cell lysate was centrifuged (4000 g, 4°C, 15 min) and aliquots of the supernatant were stored at −80°C. BALB/c-3T3 fibroblasts were seeded at a density of 3500 cells/cm 2 in 96-well plates and the culture medium was changed 3 days later. After another 3 days, when the cells had just become quiescent, the monolayer was washed once with serum-free DMEM and the cell extract samples were diluted in serum-free DMEM and added to cells. Specific neutralization of the recombinant bFGF with an antibFGF antibody (R&D Systems) was also performed. The cell survival-enhancing activity was measured after 20 h as described by Tamm et al. 45 Briefly, the monolayer was washed to remove all the detached cells, then trypsinized for 5 min. The cells were resuspended in complete medium and trypan blue, and the remaining viable cells were counted. For each 96-well plate, a standard doseeffect curve was drawn by plotting dilutions (1 pg/ml to 50 ng/ml) of the recombinant human 16 kDa bFGF protein (R&D Systems) against the number of surviving cells.
Formation of capillary tubes in a fibrin matrix model
The protein matrix model was devised according to the method of Pepper et al. 20 CPAE cells were seeded in 28 cm 2 plates. After 2 days the cells were either infected with Ad-RSVbFGF or Ad-RSV␤gal, or mock infected. Twentyfour hours PI, the cells were detached with EDTA, counted, and samples of 10 4 cells in complete MEM were put on the surface of a 1.5% agarose gel filling the wells of a 96-well plate, to form aggregates in the center of the wells. After a 24 h incubation, five to eight aggregates for each experimental treatment were sampled, put together in a four-well plate and embedded in a fibrin matrix, obtained after the coagulation of a fibrinogen solution mixed with human thrombin (1 U/ml). Complete medium containing aprotinin (2 m) was added on the surfaces of fibrin matrix. The medium was changed every 3 days. Formation of capillary tubes that arose from the periphery of endothelial cell aggregates could be observed on a microscope after 1 to 5 day cultures.
In vivo experiments
Matrigel injection: This was devised according to the method of Passaniti et al 37 modified by Mü lhauser et al.
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The growth factor-free Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA), previously thawed at 4°C, was mixed with 3 × 10 9 p.f.u. of either Ad-RSVbFGF or AdRSV␤gal or mixed with the buffer only (1:10 v/v). Along the ventral midline of 6-week-old C57BL/6 nude/nude female mice 700 l of the mixture was injected subcutaneously. Two weeks after injection, tissue containing the matrigel plugs including the adjacent skin and abdominal muscle, were sampled, fixed overnight in AFA (5% acetic acid, 75% ethyl-alcohol, 2% formol, 18% water) and embedded in paraffin. Several semi-serial 5 m thick sections were prepared and stained with hematoxylin-eosinsaffron. Vessel counts on histological slides were performed as follows. All observable capillaries in the whole Matrigel surface were counted by two investigators and in a blind manner under a Zeiss microscope (magnification ×200) and expressed as number per mm 2 .
Intramuscular injection: Forty microliters of PBS solution containing 2 × 10 9 p.f.u. of the recombinant adenovirus Ad-RSVbFGF or Ad-RSV␤gal were injected into the right or the left gastrocnemius muscle respectively of 6-weekold mdx (C57BL/10ScSn) mice, using a 30-gauge needle. Six days after injection, the gastrocnemius muscles were excised, fixed overnight in AFA, embedded in paraffin, and cut in a transverse orientation. Semi-serial 5 mthick sections were prepared.
ELISA quantification of bFGF in vivo
A high sensitivity (detection of less than 0.28 pg/ml) ELISA kit (R&D Systems) was used to quantify bFGF in the mouse sera just before injection and 6 days PI. The bFGF concentration (in pg per milliter of serum) was measured as described in the protocol provided by the supplier. The same ELISA kit was used to quantify bFGF in the gastrocnemius muscles 6 days after virus injection. Samples (0.1 g wet weight) of the excised muscles were pulverized under liquid nitrogen and homogenized in 1 ml of ice-cold buffer (50 mm Tris-HCl pH 7.4, 0.25 mm sucrose, 5 mm EDTA, 1% (w/v) SDS, 1 m aprotinin, 1 m leupeptin, 1 m pepstatin, 5 mm NEM and 1 mm PMSF). The homogenates were diluted 1/200 in 50 mm Tris-HCl pH 7.4 and centrifuged (15 000 g, 4°C, 10 min) to remove cell debris. The bFGF concentration of the supernatants was expressed in pg by mg of total protein content.
Pathology and immunohistochemistry on skeletal muscle bFGF immunodetection: Sections of gastrocnemius muscle were immunostained with different polyclonal antibodies directed against bovine bFGF (AB-33-NA; R&D Systems), E. coli-derived human bFGF (AB-233-NA), or E. coli ␤-galactosidase (ICN Pharmaceuticals, USA), respectively, using an immunoperoxidase protocol. 46 Deparaffined 5 m thick sections were incubated in blocking buffer (0.5% Triton X100, 3% (w/v) milk in PBS) for 30 min at RT. Sections were incubated overnight at 4°C with anti-bFGF or anti-␤-galactosidase antibody, respectively, diluted 1/20 in blocking buffer. Sections were incubated during 30 min with biotinylated anti-rabbit or anti-goat IgG and during 15 min with streptavidinperoxidase before addition of 3-amino-9-ethylcarbazole (AEC). Slides were counterstained with Mayer's hematoxylin.
Vessel quantification: Muscle sections were permeabilized with 10 g/ml proteinase-K at 37°C for 15 min. Endogenous peroxidase activity was quenched with 0.3% H 2 O 2 for 15 min. The sections were incubated for 15 min in blocking buffer and incubated for 1 h with a rabbit polyclonal serum raised against human von Willebrand factor (DAKO, Glostrup, Denmark) diluted 1/200. The slides were treated as above for the final steps of immunohistochemistry. Vessel counts on histological slides were performed according to a method described by Weidner et al 47 for tumors. Since these tissues are usually associated with a high vessel count, we have adapted this method. Briefly, at ×200 magnification and for each specimen, four to five representative fields were selected from the areas with the most vessels. Any reddish-stained endothelial cell or endothelial cell cluster positive for von Willebrand factor and clearly separate from an adjacent cluster was considered to be a single countable microvessel. All counts were performed by two investigators and in a blind manner.
Statistical analysis
Statistical comparisons between groups were carried out using paired or unpaired Student's t test, and a P Ͻ 0.05 was set to indicate statistical significance.
